New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
10:39 EDTZMH, MEMP, AR, TOT, SILHigh option volume stocks: ZMH MEMP AR TOT SIL
News For ZMH;MEMP;AR;TOT;SIL From The Last 14 Days
Check below for free stories on ZMH;MEMP;AR;TOT;SIL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
11:14 EDTZMHNobel Biocare working with Goldman on potential sale, Bloomberg reports
Subscribe for More Information
July 28, 2014
10:02 EDTZMHOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:42 EDTZMHZimmer upgraded at Oppenheimer
Subscribe for More Information
06:48 EDTTOTU.K. to allow more oil, gas exploration, NY Times says
Subscribe for More Information
06:29 EDTZMHZimmer upgraded to Outperform from Perform at Oppenheimer
July 24, 2014
15:11 EDTZMHZimmer valuation not reflecting Biomet deal potential, says Cantor
Cantor says Zimmer remains its preferred name in orthopedics despite its "disappointing" Q2 report, as the firm believes the stock's valuation doesn't properly reflects the potential from its tie-up with Biomet. Cantor thinks Zimmer management's synergy targets are possibly conservative and raised its price target on the stock to $117 from $113.
08:27 EDTZMHZimmer 'confident' Biomet merger transaction to be completed in 1Q15
Subscribe for More Information
08:25 EDTZMHZimmer sees FY14 gross margin ratio at 73%-74%
Expects FY14 SG&A to be unchanged, although it says there will be a seasonally higher ratio in Q3. Sees FY14 tax rate of 25.5%.
08:25 EDTZMHZimmer sees Q3 EPS $1.29-$1.31, consensus $1.37
Subscribe for More Information
08:19 EDTZMHLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
07:48 EDTZMHZimmer cuts FY14 EPS to $6.00-$6.10 from $6.00-$6.20, consensus $6.12
Subscribe for More Information
07:47 EDTZMHZimmer reports Q2 adjusted EPS $1.49, consensus $1.49
Reports Q2 revenue $1.18b, consensus $1.21B
July 22, 2014
08:15 EDTZMHZimmer should be bought on any weakness from Q2 results, says RBC Capital
RBC Capital believes that consensus Q2 recon estimates for Zimmer may be "a bit optimistic," but the firm thinks that investors already partially anticipate a miss on that metric The firm recommends buying the stock on any weakness associated with Q2 results, as it thinks the company's valuation is favorable, given its growth outlook. RBC Capital keeps a $120 price target and Outperform rating on the shares.
July 17, 2014
16:31 EDTARAntero Resources sees meeting 2014 production guidance
Subscribe for More Information
16:31 EDTARAntero Resources reports Q2 average daily gas equivalent production 891 MMcfe/d
Subscribe for More Information
10:00 EDTAROn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:09 EDTARAntero Resources initiated with a Market Perform at FBR Capital
Subscribe for More Information
July 16, 2014
17:36 EDTARAntero Resources initiated with a Buy at Canaccord
Target $75.
July 15, 2014
16:11 EDTARAntero Resources reports mid-year FY14 reserves up 19% to 9.1 Tcfe
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use